18 Jun 2019 --- Researchers have discovered one of the first concrete examples of how the microbiome can interfere with a drug’s intended path through the body. Focusing on levodopa (L-dopa), a treatment for Parkinson's disease, they identified which bacteria are responsible for degrading the drug and how to stop this microbial interference. The findings point to the importance of further research into the microbiome and how it – combined with the nutrients we consume – affects our health.
